What’s the full story? DD shares exhibited a robust reaction in the 1.5 days following the announcement, rising approximately 3%. The feedback from investors was positive - the prospect of operating as standalone businesses should generate value through targeted growth and portfolio clarity. Additionally, Citi sees potential from an electronics recovery and the easing of destocking in more challenged markets.

The most significant source of resistance lies in valuation, particularly concerning Electronics and then New DuPont (RemainCo). Upon revisiting the Sum of the Parts in the new construct, The analysts’ views are more reflective of solid earnings from electronics over the next 18 months.

Citi sees the potential for more detail on the separation as potential positive catalysts throughout the year.

Buy at Citi means “Buy (1) ETR of 15% or more or 25% or more for High risk stocks.”

How did the stock react? Dupont opened the regular session at $82.44 and closed at $82.08, a gain of 1.18% from the prior day's regular close.

Mind Medicine

What happened? On Wednesday, well Tuesday after hours, Baird initiated coverage on Mind Medicine Inc (NASDAQ:MNMD) at Outperform with a $27 price target.

What’s the full story? Baird’s optimistic stance is primarily driven by the promising prospects of the company’s lead drug, MM120, a novel form of LSD designed to treat generalized anxiety disorder (GAD). In a pivotal phase 2b clinical trial, MM120 demonstrated a statistically significant improvement in GAD symptoms compared to a placebo. The results are particularly noteworthy as the observed therapeutic effect of MM120 was not only rapid in onset but also sustained over the entire 12-week duration of the study.